AMRX

Handel nachbörslich: 8.20 -0.04 -0.49%

Amneal Pharmaceuticals Inc (AMRX)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Amneal Pharmaceuticals Inc

Healthcare (1170)

908-947-3120

400 Crossing Boulevard, 3rd Floor, Bridgewater

@amnealpharma

Nächster Verdiensttermin

Neueste SEC-Einreichungen

AMRX's Discussions on Twitter

Vergleichen Sie AMRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AMRX Amneal Pharmaceuticals Inc	8.24	2.61B	2.68B	-184.45M	229.23M	-0.6805
ZTS Zoetis Inc	150.03	70.46B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.74	47.78B	30.08B	710.16M	4.45B	0.2182
HLN Haleon Plc Adr	9.59	45.15B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.31	19.16B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	297.33	13.56B	2.99B	1.21B	1.13B	25.06

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-06	Eingeleitet	Goldman	Buy
2025-02-24	Hochstufung	JP Morgan	Neutral → Overweight
2024-09-06	Hochstufung	JP Morgan	Underweight → Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Sector Perform
2021-03-08	Hochstufung	Goldman	Sell → Buy
2020-12-14	Hochstufung	Barclays	Equal Weight → Overweight
2020-12-14	Hochstufung	Guggenheim	Neutral → Buy
2020-07-27	Eingeleitet	Goldman	Sell
2020-05-12	Hochstufung	Guggenheim	Sell → Neutral
2019-12-12	Herabstufung	Raymond James	Outperform → Mkt Perform
2019-11-12	Herabstufung	JP Morgan	Neutral → Underweight
2019-11-07	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2019-07-22	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-07-11	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2019-07-08	Hochstufung	Piper Jaffray	Neutral → Overweight
2019-06-11	Eingeleitet	Barclays	Equal Weight
2019-05-21	Hochstufung	Raymond James	Mkt Perform → Strong Buy
2019-03-20	Eingeleitet	SunTrust	Buy
2019-03-08	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2018-12-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2018-10-16	Herabstufung	SunTrust	Buy → Hold
2018-08-13	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2018-07-23	Eingeleitet	Morgan Stanley	Overweight
2018-06-22	Eingeleitet	B. Riley FBR, Inc.	Buy

Alle ansehen

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Vergleichen Sie AMRX mit anderen Aktien

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Parkinson's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com

Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension - MSN

Amneal to Report Second Quarter 2025 Results on August 5, 2025 - GlobeNewswire

Amneal Earnings: How to Join Q2 2025 Results Call on August 5 - Stock Titan

Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares - Insider Monkey

Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? - Nasdaq

5 Revealing Analyst Questions From Amneal’s Q1 Earnings Call - Yahoo Finance

Amneal reports positive phase 3 results for XOLAIR biosimilar By Investing.com - Investing.com Nigeria

Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmac - GuruFocus

Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Parkinson’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma - Barchart.com

Parkinson's Disease Market to Show Remarkable Growth Trends - openPR.com

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - Yahoo Finance

Epinephrine Autoinjector Market Size, Share, and Competitive - openPR.com

FDA approves Amneal’s prednisolone acetate eye drops, launch set for Q3 - Investing.com India

FDA approves Amneal's prednisolone acetate ophthalmic suspension - Eyes On Eyecare

Insider Sell: Gautam Patel Sells 56,426 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate - TipRanks

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension - MarketScreener

Amneal Pharmaceuticals (AMRX) Gains FDA Approval for Eye Drug | AMRX Stock News - GuruFocus

FDA Green Lights Amneal's $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative - Stock Titan

Amneal Recalls Oral Antibiotic Over Contamination Issue - Infectious Disease Advisor

Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN

Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision By Investing.com - Investing.com Canada

Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision - Investing.com

Selective Estrogen Receptor Modulators Market Research 2025-2030: Leading Players Shaping the Future of Selective Estrogen Receptor Modulators Industry - GlobeNewswire Inc.

Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) PT at $11.60 - Defense World

Wellington Management Group LLP Has $586,000 Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Amneal Pharmaceuticals (NASDAQ:AMRX) Coverage Initiated by Analysts at The Goldman Sachs Group - Defense World

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.52 Million Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? - Benzinga

Teva stock, Amneal stock, rated Buy at Goldman (TEVA:NYSE) - Seeking Alpha

Amneal recalls oral antibiotic due to bacterial contamination - MSN

AMRX Stock Coverage Initiated with Buy Rating by Goldman Sachs | AMRX Stock News - GuruFocus

Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating - Investing.com

Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating By Investing.com - Investing.com UK

Two Sigma Advisers LP Sells 32,400 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Amneal Pharmaceuticals at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Amneal Pharmaceuticals Initiates Nationwide Recall of Contaminated Sulfamethoxazole/Trimethoprim Tablets - Insider Monkey

Amneal Pharmaceuticals (AMRX) Recalls Antibiotic Due to Contamination - GuruFocus

Amneal announces recall of oral antibiotic (AMRX:NASDAQ) - Seeking Alpha

Amneal Pharmaceuticals (AMRX) Recalls Contaminated Tablets Due t - GuruFocus

Amneal Recalls Three Lots of Urinary Tract Infection Tablets - marketscreener.com

Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade - sharewise.com

Amneal Recalls Three Lots Of UTI Drug Over Concerns of Microbial Contamination: Retail Sticks To Bearish Territory - Stocktwits

Amneal Pharmaceutical LLC Issues a Nationwide Recall of Sulfamethoxazole / Trimethoprim Tablets, USP, 400 mg/80 mg Only, Due to Microbial Contamination - US Recall News

Amneal to Participate at Upcoming Investor Conferences in June - GlobeNewswire

Amneal CEO and CFO Set for Exclusive Presentations at Two Major Healthcare Investor Conferences - Stock Titan

Bank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

FDA approves Amneal’s DHE migraine/cluster headache autoinjector - MSN

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $716,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie AMRX